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ABSTRACT
Objectives: To examine whether the extent of
ﬁbroproliferative changes on high-resolution CT (HRCT)
scan inﬂuences prognosis, ventilator dependency and
the associated outcomes in patients with early acute
respiratory distress syndrome (ARDS).
Design: A prospective observational cohort study.
Setting: Intensive care unit in a teaching hospital.
Participants: 85 patients with ARDS who met
American-European Consensus Conference Criteria
and eligible criteria.
Interventions: HRCT scans were performed and
prospectively evaluated by two independent observers
on the day of diagnosis and graded into six ﬁndings
according to the extent of ﬁbroproliferation. An overall
HRCT score was obtained by previously published
method.
Primary and secondary outcomes: The primary
outcome was 60-day mortality. Secondary outcomes
included the number of ventilator-free days, organ
failure-free days, the incidence of barotraumas and the
occurrence of ventilator-associated pneumonia.
Results: Higher HRCT scores were associated with
statistically signiﬁcant decreases in organ failure-free
days as well as ventilator-free days. Multivariate Cox
proportional hazards model showed that the HRCT
score remained an independent risk factor for mortality
(HR 1.20; 95% CI 1.06 to 1.36; p¼0.005). Multivariate
analysis also revealed that the CT score had predictive
value for ventilator weaning within 28 days (OR 0.63;
95% CI 0.48 to 0.82; p¼0.0006) as well as for an
incidence of barotraumas (OR 1.61; 95% CI 1.08 to
2.38; p¼0.018) and for an occurrence of ventilator-
associated pneumonia (OR 1.46; 95% CI 1.13 to 1.89;
p¼0.004). A HRCT score <210 enabled prediction of
60-day survival with 71% sensitivity and 72%
speciﬁcity and of ventilator-weaning within 28 days
with 75% sensitivity and 76% speciﬁcity.
Conclusions: Pulmonary ﬁbroproliferation assessed
by HRCT in patients with early ARDS predicts
increased mortality with an increased susceptibility to
multiple organ failure, including ventilator dependency
and its associated outcomes.
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ARTICLE SUMMARY
Article focus
- Whether the extent of ﬁbroproliferation on high-
resolution CT (HRCT) scan at the time of diagnosis
of acute respiratory distress syndrome (ARDS)
would impact 60-day and 180-day mortality?
- Whether the extent of ﬁbroproliferation on HRCT
scan at the time of diagnosis of ARDS would
impact ventilator dependency and its associated
outcomes?
- Whether the extent of ﬁbroproliferation on HRCT
scan at the time of diagnosis of ARDS would
impact multiple organ failure?
Key messages
- Pulmonary ﬁbroproliferation assessed by HRCT
in patients with early ARDS predicts increased
mortality.
- Pulmonary ﬁbroproliferation assessed by HRCT
in patients with early ARDS predicts ventilator
dependency and its associated outcomes (baro-
traumas, ventilator-associated pneumonia).
- Pulmonary ﬁbroproliferation assessed by HRCT
in patients with early ARDS increases suscepti-
bility to multiple organ failure.
Strengths and limitations of this study
- The CT score is based on our previous published
studies correlating HRCT ﬁndings with pathology
and has been evaluated in the other diseases.
- A relatively small number of patients from
a single institution.
- Lack of correlation with either clinical parameters
or pathologic ﬁndings.
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Open Access ResearchINTRODUCTION
The acute respiratory distress syndrome (ARDS) is the
most severe form of a wide spectrum of pathological
conditions designated as acute lung injury.
1 2 ARDS is
considered to have an early and a late phase and is
pathologically classiﬁed into three stages
3 in which an
initial inﬂammatory injury with protein-rich oedema and
haemorrhage is followed by ﬁbroproliferation, during
which ﬁbroblasts proliferate with organisation and
subsequent collagen deposition, resulting in lung
remodelling, ultimately leading to ﬁbrotic lung disease.
The histological features of ARDS represent a poorly
deﬁned time-dependent stereotypic response to acute
lung injury and are pathologically designated as diffuse
alveolar damage.
34Fibroproliferation is part of the
tissue host defense responseda tissue-protective reac-
tion that consists of an integrated network of three
simultaneously activated pathways (inﬂammation, coag-
ulation and tissue repair (ﬁbroproliferation is one
component of tissue repair)), which account for the
histologic and physiologic changes observed with
progression (maladaptive response) or resolution
(adaptive response) of ARDS and multiple organ failure
syndrome.
5 Although pathologic staging may be
conceptually useful, improvement versus worsening in
physiological parameters (ie, PaO2/FiO2 ratio, etc) over
time correlates with adaptive versus maladaptive lung
repair and outcome. Clinicians can use pathophysiology
(shunt vs V/Q mismatch with increasing deadspace) to
distinguish the transition from exudative to ﬁbroproli-
ferative ARDS; however, few features, except probably
time, allow them to distinguish these pathological phases
without a lung biopsy.
67
Data regarding the signiﬁcance of a ﬁbroproliferative
response on mortality risk assessed using bron-
choalveolar lavage or tracheal aspirate in ARDS patients
are available.
8e11 High-resolution CT (HRCT) ﬁndings
correlate with the pathologic phases of diffuse alveolar
damage.
12e15 Furthermore, we have previously reported
on the prognostic value of HRCT in determining the
extent of ﬁbroproliferation in ARDS patients.
16 Based on
HRCT appearance, less ﬁbroproliferation in early ARDS
was associated with greater ventilator-free days and less
barotraumas.
16 Because ARDS is a systemic disease with
systemic inﬂammation, core pathogenetic process affects
the lung as well as extrapulmonary vital organs. In this
prospective study, we evaluated what was found in the
retrospective study
16 and the relationship between early
ﬁbroproliferation and the progression to multiple organ
failure and whether the extent of ﬁbroproliferation on
HRCT scan at the time diagnosis of ARDS would impact
the susceptibility for ventilator dependency and its
associated complications and on the mortality.
METHODS
One hundred and ﬁfty-two patients with ARDS diag-
nosed according to the American-European Consensus
Conference Criteria
17 were enrolled from 1 October
2004 to 31 July 2008 at our institution. This study was
approved by an institutional review board of our
hospital, and informed consent was obtained from the
participants or their families. On the basis of the survival
in our retrospective study of 44 patients,
16 we designated
the number of patients more than 80 at least.
Patients
Eligible patients were receiving mechanical ventilation
by tracheal tube (n¼79) or mask for non-invasive posi-
tive pressure ventilation (n¼6). Furthermore, HRCT
scan was performed on the day of diagnosis of ARDS by
their consent. Exclusion criteria were shown in ﬁgure 1.
Especially, pre-existing chronic interstitial lung diseases
were strictly excluded by history taking, imaging data
available before onset of ARDS and the presence of
coarse reticulation and honeycombing on HRCT scans
suggesting of chronic pulmonary ﬁbrosis. Furthermore,
the other pre-existing pulmonary disease such as
pulmonary emphysema was documented from review of
radiological reports. Information about our patients’
severity and characteristics is reported in table 1.
HRCT examination, assessment and scoring
All patients underwent whole lung volumetric HRCT
scanning of the chest on the day of diagnosis of ARDS
using a multidetector-row CTscan. All multidetector-row
CTscans were obtained with 2-mm thickness and 15-mm
table speed per rotation and were performed at full
inspiration from the lung apex to base. Contiguous CT
slices were reconstructed using a high-spatial frequency
algorithm. Sections were displayed at 10-mm intervals
throughout the chest with the patient in the supine
position and without intravenous contrast medium. The
process did not negatively affect the patients’ condition.
In this study, we evaluated single CTscan acquired at day
1 of the ARDS diagnosis because sequential CT scans
were hard to be performed after high positive end-
expiratory pressure ventilation was introduced. HRCT
Figure 1 Outlines of the study.
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Fibroproliferative changes on HRCT in early ARDSscans were evaluated on the day of ARDS diagnosis by
two independent observers (KF and TJ) who were chest
radiologists with 23 and 20 years of experience, respec-
tively, and were unaware of patient condition. The
presence and extent of areas of ground-glass attenua-
tion, air-space consolidation, traction bronchiectasis,
traction bronchiolectasis and honeycombing were
assessed. Ground-glass attenuation was deﬁned as a hazy
area with increased opaciﬁcation without obscuration of
underlying vascular markings. Air-space consolidation
was considered present when the vascular markings were
obscured. When bronchi were irregular in contour, the
dilated bronchus within areas of parenchymal abnor-
mality was recognised as traction bronchiectasis. Trac-
tion bronchiolectasis was identiﬁed by the presence of
dilated bronchioles within areas with parenchymal
abnormality. Honeycombing was deﬁned as the presence
of cystic airspaces measuring 2e10 mm in diameter with
well-deﬁned walls.
HRCT ﬁndings were graded on a scale of 1e6 based
on the classiﬁcation system correlating with previously
described pathology (ﬁgure 2)
14 16: 1, normal attenua-
tion; 2, ground-glass attenuation; 3, consolidation; 4,
ground-glass attenuation with traction bronchiolectasis
or bronchiectasis; 5, consolidation with traction bron-
chiolectasis or bronchiectasis and 6, honeycombing. The
presence of each of these six abnormalities was assessed
independently in three (upper, middle and lower) zones
of each lung. The upper zone was deﬁned as the area
above the level of the carina, the middle zone as the area
Table 1 Clinical characteristics of patients on the day of ARDS onset
Characteristic Total (n[85)
60 days Outcomes
p Value
Survivors
(n[54)
Non-survivors
(n[31)
Age (years)* 75610 75611 76610 0.60
Sex (male/female) 51/34 30/24 21/10 0.38
Cigarette smoking 33 17 16 0.11
Presence of emphysema 32 18 14 0.39
Liver cirrhosis (%) 6 (7.1) 4 (7.4) 2 (6.5) >0.99
Direct/indirect injury 59/26 38/16 21/10 0.81
PaO2:FiO2 96.2645.6 96.5645.0 96.2647.5 0.90
Causes of lung injury
Pneumonia (%) 32 (37.6) 20 12 >0.99
Sepsis (%) 24 (28.2) 13 11 0.38
Pulmonary (%) 11 (12.9) 5 6 0.20
Extrapulmonary (%) 13 (15.2) 8 5 >0.99
Aspiration (%) 22 (25.9) 16 6 0.44
Others (%) 7 (8.2) 5 2 >0.99
Lung injury score* 3.260.5 3.360.5 3.360.5 0.88
APACHE II score 21.064.7 21.064.6 22.064.9 0.76
SOFA score 7.062.8 7.062.8 6.062.9 0.15
McCabe score (1/2/3) 78/5/2 49/4/1 29/1/1 >0.99
DIC score* y 2.461.7 2.461.7 2.561.6 0.68
White blood cell count (per mm
3) 1060066788 1060066178 1060067839 0.63
C reactive protein (mg/dl) 15.4610.3 15.469.6 16.1611.5 0.69
Albumin (g/dl) 3.060.5 3.160.5 2.860.5 0.11
Lactate dehydrogenase (IU/l) 3086185 3016147 3396235 0.29
Platelet count (per mm
3) 20.1610.7 20.7611.0 18.9610.3 0.94
Days of CT scanning from
ARDS onset (day)
1.060.0 1.060.0 1.060.0 >0.99
HRCT scorey 207653 196654 233646 0.001
Initial steroid therapy
High dose 14 7 7 0.36
Low dose 71 47 24 0.36
Ventilatory variables
Tidal volume, ml/kg predicted
body weight
8.060.8 8.060.7 8.060.9 0.54
Plateau pressure, cmH2O 21.564.2 21.063.8 23.064.7 0.34
Initial PEEP, cmH2O 8.063.4 8.062.5 8.064.3 0.18
Data are expressed as median 6 SD.
*Data are mean 6 SD. The p values refer to comparisons between survivors and non-survivors.
yScore $4 deﬁned as disseminated intravascular coagulation from scoring system for The Japanese Association for Acute Medicine.
APACHE II, acute physiology and chronic health evaluation II; ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular
coagulation; HRCT, high-resolution CT; PEEP, positive end-expiratory pressure; SOFA, sequential organ failure assessment.
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Fibroproliferative changes on HRCT in early ARDSbetween the level of the carina and that of the infra-
pulmonary vein and the lower zone as the area below the
level of the infrapulmonary vein. The extent of each
abnormality was determined by visually estimating the
percentage (to the nearest 10%) of the affected lung
parenchyma in each zone. The assessments of the two
observers were averaged. The abnormality score for each
zone was calculated by multiplying the percentage area
by the point value (1e6). The six zone scores were
averaged to determine the total score for each abnor-
mality in each patient. The overall CT score for each
patient was obtained by adding the six averaged scores.
The scoring system is previously reported
14 16 and has
been evaluated in the other diseases.
18 19
Treatment protocol
All patients underwent a common intensive treatment
according to the domestic clinical practical guide-
lines.
20e24 Antibiotic therapy was performed by these
guidelines, which were referenced to the American
Thoracic Society/Infectious Diseases Society of
America Consensus Guidelines on the management of
community-acquired pneumonia in immunocompetent
adults.
25 26
While there is contradicting reports for a survival
beneﬁt, all randomised trials have shown a signiﬁcant
reduction in duration of mechanical ventilation.
27e30
When this study protocol was made, the efﬁcacy of
prolonged corticosteroids to the ﬁbroproliferative
ARDS had been reported in a small randomised control
study.
30 In the current study, we examined the rela-
tionship between the efﬁcacy of steroids and the
extent of ﬁbroproliferation on HRCT scans. According
to our previous study,
16 early ﬁbroproliferation on
HRCT scans was observed in 64% of 44 patients with
ARDS. Therefore, we started corticosteroid therapy
after performing HRCTscans at the diagnosis of ARDS.
Initial administration of methylprednisolone with
a moderate dose (2 mg/kg/day) (n¼71) or high dose
( 1 0 0 0m g / d a yf o r3d a y sf o l l o w e db yam o d e r a t ed o s e )
(n¼14) was introduced and was gradually tapered
over 1 month according to the previous study.
30 Venti-
lator management and ventilator weaning was intro-
duced by the evidence-based guidelines
23 24 with
reference to the lower tidal volume (VT)s t r a t e g y( 6m l /
kg predicted body weight < VT <10 ml/kg predicted
body weight) in the ARDS Clinical Trial
31 and to
the guidelines for weaning and discontinuing ventila-
t o r ys u p p o r tf r o mt h eA m e r i c a nC o l l e g eo fC h e s t
Physicians.
32
Screening of ventilator-associated outcomes
For each patient, we recorded the number of
ventilator-free days. Barotrauma, deﬁned as any new
pneumothorax, pneumomediastinum or subcutaneous
emphysema, was noted as present or absent on routine
chest radiographs or chest tube insertions for known or
suspected spontaneous pneumothorax during the ﬁrst
28 days.
33
Ventilator-associated pneumonia (VAP) surveillance
was incorporated into the routine examinations of
cultures of sputum obtained using a sterile intratracheal
suction tube.
34 VAP was deﬁned as pneumonia occurring
after more than 48 h of mechanical ventilation and for
up to 72 h after weaning.
Organ or system failure
Patients were monitored daily for 28 days for signs of the
failure of extrapulmonary organs and systems according
to the ARDS Clinical Trial.
31 The number of days without
organ or system failure was calculated by subtracting the
number of days with organ failure from the lesser of
28 days or the number of days to death. The Sequential
Organ Failure Assessment (SOFA) score was sequentially
monitored at Days 7 and 14, except for patients who died
within 7 days or 14 days.
Figure 2 High-resolution CT
ﬁndings correlated with pathology.
(A) High-resolution CT ﬁndings
corresponding to exudative phase
of acute respiratory distress
syndrome (ARDS). HRCT scan at
the level of right middle lobe
shows dependent airspace
consolidation without traction
bronchiectasis and non-
dependent areas of sparing. The
patient was a 68-year-old man
with ARDS due to Streptococcus
pneumonia. (B) High-resolution
CT ﬁndings corresponding to
ﬁbroproliferative phase of ARDS. HRCT scan at the level of right lower lobe shows extensive airspace consolidation and ground-
glass attenuation associated with traction bronchiectasis (arrows). The patient was an 84-year-old woman with ARDS due to
sepsis. (C) High-resolution CT ﬁndings corresponding to ﬁbrotic phase of ARDS. HRCT scan at the level of right inferior pulmonary
vein shows extensive ground-glass attenuation associated with traction bronchiectasis (arrows), coarse reticulation and cystic
changes (arrowheads). The patient was a 65-year-old woman with ARDS due to viral pneumonia. (Sequential changes of HRCT
ﬁndings were shown in the supplemental ﬁgure.)
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Fibroproliferative changes on HRCT in early ARDSOutcome measurements
The primary outcome was mortality 60 days after ARDS
diagnosis. Patients discharged from the hospital while
alive for 60 days were deﬁned as survivors. Their prog-
noses were eventually followed until 180 days. Non-
survivors were deﬁned as patients who died in the
hospital. Secondary outcome variables included the
number of ventilator-free days, organ failure-free days,
the incidence of barotraumas and the occurrence of
ventilator-associated pneumonia.
Statistical analysis
Cox proportional hazards regression analysis was used to
examine the inﬂuence on survival of 10% change of
radiologically ﬁbroproliferation on HRCTwhile adjusting
for other prognostic clinical factors, such as age, severity
of illness and non-pulmonary organ dysfunctions, that
had been reported.
35e37 Multivariate regression analysis
was also performed to assess the impact on ventilator-
weaning failure within 28 days, an incidence of baro-
traumas and ventilator-associated pneumonia. To analyse
the CTscore as a predictor of survival or of the failure of
ventilator weaning or of the occurrence of barotrauma
within 28 days after the onset of ARDS, we used receiver-
operator characteristic (ROC) curves and the corre-
sponding area under the curve (AUC) to evaluate how
the prediction model preformed on the test data and to
determine the cut-off value of the CT score yielding the
highest sensitivity and speciﬁcity which were determined
by the Youden index (ie, sensitivity + speciﬁcity   1).
Statistical analyses were performed by using the SPSS
package (V.18.0J; SPSS). For all statistical analyses,
p<0.05 was considered signiﬁcant.
RESULTS
Baseline clinical characteristics
Non-survivors had more severe lung injury with ﬁbro-
proliferative changes on HRCT scan as shown by their
higher HRCT scores than survivors, although non-survi-
vors tended to have less severe multiorgan failure as
expressed by their lower SOFA scores. No signiﬁcant
differences were seen between survivors and non-survi-
vors in the number of a history of cigarette smoking and
a presence of emphysema. No signiﬁcant differences
were also observed in the ventilatory and medicational
conditions as well (table 1).
HRCT ﬁndings for survivors and non-survivors
The area of increased attenuation associated with trac-
tion bronchiolectasis or bronchiectasis, indicative of
radiologically ﬁbroproliferation, was observed in 40
(47%) of 85 patients at presentation and was signiﬁ-
cantly smaller in survivors than in non-survivors (table
2), whereas the area of increased attenuation without
traction bronchiolectasis or bronchiectasis was greater in
survivors than in non-survivors. Interobserver variability
in evaluation of the presence of lung abnormalities was
good (k, 0.63e0.83), and the assessments of the extent
of abnormality by two different observers also correlated
well (Spearman rank correlation coefﬁcient, 0.72;
p<0.01).
Prognostic value of the HRCT score
The overall HRCT score of survivors (median 6 SD,
195.7653.7; range, 133.4e325.0) was signiﬁcantly
smaller than that of non-survivors (233.1646.2;
174.8e384.8). Construction of a ROC curve yielded an
optimal cut-off value of the HRCTscore of 210 which was
determined for prediction of survival at day 60 with 71%
sensitivity and 72% speciﬁcity (AUC, 0.71; 95% CI 0.61
to 0.82) and for prediction of survival at day 180 with
71% sensitivity and 76% speciﬁcity (AUC, 0.73; 95% CI
0.62 to 0.84) (ﬁgure 3). A signiﬁcant difference was
observed in the 60-day mortality rate between patients
with CT score <210 and those with CT score $210
(p<0.0001) as well as in the ventilator-free days at day 28
(p<0.0001) (table 3). The difference in the 60-day
mortality rate between patients with more or less ﬁbro-
proliferative changes on HRCT scan persisted regardless
of causes of ARDS (ﬁgure 4). Multivariate Cox
Table 2 Extent of each high-resolution CT ﬁnding in 60-day survivors and non-survivors of ARDS
CT ﬁnding Survivors (n[54) Non-survivors (n[31) p Value
Spared area 37.0619.2 30.3614.9 0.15
Ground-glass attenuation 33.5622.9 30.0616.0 0.70
Air-space consolidation 17.5613.8 18.3619.3 0.72
Total area without traction bronchiolectasis
or bronchiectasis
88.0622.0 78.2622.5 0.01
Ground-glass attenuation plus traction
bronchiolectasis or bronchiectasis
9.3617.8 16.6621.7 0.08
Air-space consolidation plus traction
bronchiolectasis or bronchiectasis
2.467.8 5.6610.3 0.01
Honeycombing 0.060.0 0.060.0 NS
Total area with traction bronchiolectasis
or bronchiectasis
11.8618.0 22.1624.3 0.01
Data are mean 6 SD of percentage of lung involvement. ManneWhitney U test.
ARDS, acute respiratory distress syndrome.
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Fibroproliferative changes on HRCT in early ARDSproportional hazards model with adjustment for demo-
graphic characteristics, severity of illness, non-pulmo-
nary organ dysfunctions and HRCT score at diagnosis,
the HRCTscore remained an independent risk factor for
mortality (HR 1.20; 95% CI 1.06 to 1.36; p¼0.005) when
expressed as mortality change per 10% increase in the
area of attenuation with traction bronchiolectasis or
bronchiectasis on HRCT scans (tables 4 and 5).
Relation between the HRCT score and the number of
ventilator-free days and the number of organ failure-free
days and sequential changes of SOFA score
An ROC curve determined the best cut-off value of the
CT score of 210 for prediction of ventilator-weaning
failure within 28 days with 75% sensitivity and 76%
speciﬁcity (AUC, 0.77; 95% CI 0.67 to 0.88) (ﬁgure 5).
Regardless of signiﬁcantly higher SOFA score (8.063.0
vs 5.062.0; p<0.0001) and higher disseminated intra-
vascular coagulation score (2.861.5 vs 1.961.8;
p<0.002) at diagnosis, patients with a CT score of <210
had a signiﬁcantly higher number of ventilator-free days
(14.067.8 vs 5.268.0 days; p<0.0001). Those patients
with a lower CT score were associated with less severe
subsequent multiorgan failure as shown by a signiﬁcantly
higher number of organ failure-free days (table 3) and
by signiﬁcant decrease of sequential SOFA score than
that of patients with a higher CT score (ﬁgure 6).
Multivariate regression analysis, with adjustment for
demographic characteristics, general severity and
occurrence of barotraumas, showed that the CT score
was independently associated with ventilator weaning
within 28 days with an OR of 0.63 when expressed as
weaning failure change per 10% increase in the area of
attenuation with traction bronchiolectasis or bronchi-
ectasis on HRCT scans (p¼0.0006) (table 6A).
Relation between the HRCT score and the incidence of
barotraumas or ventilator-associated pneumonia
All 11 patients with barotrauma had pneumothorax.
Barotrauma occurred 3e28 days (mean 6 SD,
12.769.4 days) after ARDS onset. An ROC curve identi-
ﬁed the optimal cut-off value of the CT score of 235 for
prediction of barotrauma onset with 73% sensitivity and
77% speciﬁcity (AUC, 0.77; 95% CI 0.59 to 0.95) (ﬁgure
7A). Patients with the CT score <235 had a signiﬁcantly
lower incidence of barotrauma (5.0 vs 32.0%; p¼0.0019)
within 28 days after the onset of ARDS than those with
CT score of $235 (ﬁgure 7B). The CT score was also
independently associated with the occurrence of baro-
traumas with an OR of 1.61 by multivariate regression
analysis (p¼0.018) (table 6B). VAP was documented in
36 patients (42.3%) after day 5 since ARDS onset. The
Figure 3 Receiver operator characteristic (ROC) curve of
prognostic value of the high-resolution CT score. ROC
identiﬁed the optimal cut-off value of 210 determined by the
Youden Index for prediction of survival at day 60 with 71%
sensitivity and 72% speciﬁcity (area under the curve, AUC,
0.71; 95% CI 0.61 to 0.82) and for prediction of survival at day
180 with 71% sensitivity and 76% speciﬁcity (AUC, 0.73; 95%
CI 0.62 to 0.84).
Table 3 Comparison of primary and secondary outcomes between the cut-off value showing extent of ﬁbroproliferative
changes on high-resoluiton CT at the onset of ARDS
Variable
High-resolution CT score
p Value <210 (n[47) ‡210 (n[38)
60-day mortality (%) 19.1 57.9 <0.0001
No. of hospital death 9 22
Causes of death
Multiple organ failure 8 18
Respiratory failure 1 4
No. of ventilator-free days at day 28 14.367.6 5.168.0 <0.0001
No. of organ failure-free days
Cardiovascular failure 22.468.1 16.1610.9 0.009
Coagulation abnormalities 23.068.9 17.8610.4 0.017
Hepatic failure 23.368.2 19.669.5 0.11
Renal failure 21.7610.9 19.669.6 0.29
No. of incidence of barotraumas (%) 3 (6.4) 8 (21.1) 0.056
No. of ventilator-associated pneumonia (%) 16 (34.0) 20 (52.6) 0.13
Plus or minus values are mean 6 SD. Continuous variables with non-normal distribution were compared with the use of ManneWhitney U test
and categorical variables with Fisher’s exact test.
ARDS, acute respiratory distress syndrome.
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Fibroproliferative changes on HRCT in early ARDSpercentage of patients complicated with VAP in the
higher CTscore group tended to be higher than those in
the lower CT score groups (51.4% and 35.4%, respec-
tively; p¼0.14). Multivariate analysis also demonstrated
that the CT score was independently associated with the
complication of VAP with an OR of 1.46 (p¼0.0041)
(table 6C).
DISCUSSION
Regardless of the cause of ARDS, we found the extent of
ﬁbroproliferative changes on HRCT at diagnosis of
ARDS was an independent predictive factor for survival
and ventilator dependency. Furthermore, patients with
extensive ﬁbroproliferative changes on HRCT scan were
more susceptible to associated multiorgan failure, baro-
traumas and ventilator-associated pneumonia than those
with less extensive changes. Semiquantitative determi-
nation of ﬁbroproliferation by means of HRCT assess-
ment was informative with regard to the potential for
response to treatment and for susceptibility to subse-
quent ventilator-associated outcomes (ventilator depen-
dency, barotraumas and ventilator-associated
pneumonia).
Biochemical evidence of ﬁbroproliferation is present
early in the acute lung injury process. N-terminal
procollagen peptide III (N-PCP-III) is a marker of
collagen turnover and is elevated in bronchoalveolar
lavage (BAL) ﬂuid and tracheal aspirate from ARDS
patients within 24 h of diagnosis.
8e11 The increased N-
PCP-III concentration in BALF at diagnosis was associ-
ated with poor prognosis, suggesting that pulmonary
early ﬁbroproliferation is an important determinant of
outcome.
8e11 In the present study, traction bronchiec-
tasis within areas of increased attenuation, suggesting
radiologically ﬁbroproliferation, was already detectable
on HRCTscans obtained on the day of ARDS onset in 40
patients (47%). We also conﬁrmed that HRCT ﬁndings
of early and late phase of ARDS frequently overlapped.
These results supported the previous reports and
suggested that a clinically early time point does not
necessarily correspond to a pathologically early phase of
Figure 4 (A) Day 60-mortality
rate of each major cause of acute
respiratory distress syndrome. (B)
Day 60-mortality rate compared
between the optimal cut-off value
of high-resolution CT score in
each cause. Regardless of the
cause, the mortality rate of
a patient with a lower CT score
was signiﬁcantly lower than that of
a patient with a higher CT score.
Table 4 Univariate Cox regression analysis of variables
potentially associated with mortality at day 180 in patients
with ARDS
Variable p Value HR (95% CI)
HRCT score 0.0019 1.22* (1.08 to 1.38)
Age 0.5411 0.99 (0.96 to 1.02)
Sepsis 0.4020 1.34 (0.67 to 2.67)
APACHE II score 0.6578 0.98 (0.92 to 1.06)
SOFA score 0.1724 0.92 (0.82 to 1.04)
McCabe score 0.9609 0.98 (0.41 to 2.32)
PaO2/FiO2 ratio 0.6119 1.00 (0.99 to 1.01)
Serum albumin 0.0982 0.57 (0.30 to 1.11)
*Expressed as mortality change per 10% increase in area of
attenuation with traction bronchiectasis on high-resolution CT.
APACHE II, acute physiology and chronic health evaluation II;
ARDS, acute respiratory distress syndrome; HRCT, high-resolution
CT; SOFA, sequential organ failure assessment.
Table 5 Multivariate Cox regression analysis of
prognostic factors associated with mortality at day 180 in
patients with ARDS
Variable p Value HR (95% CI)
HRCT score 0.0051 1.20* (1.06 to 1.36)
Serum albumin 0.2618 0.67 (0.33 to 1.36)
*Expressed as mortality change per 10% increase in area of
attenuation with traction bronchiectasis on high-resolution CT.
HRCT, high-resolution CT; ARDS, acute respiratory distress
syndrome.
Ichikado K, Muranaka H, Gushima Y, et al. BMJ Open 2012;2:e000545. doi:10.1136/bmjopen-2011-000545 7
Fibroproliferative changes on HRCT in early ARDSARDS. Given that no signiﬁcant difference in the cause
of ARDS was apparent between the survivors and non-
survivors in this study, no correlation between the HRCT
score and the clinical duration of ARDS may also be
attributable to differences in individual sensitivity to
lung injury and in the intensity of the consequent
exaggerated inﬂammation that occurs between the onset
of injury and progression to ARDS. The term ‘ﬁbropro-
liferative’ ARDS may not necessarily apply only to ‘late
phase’ ARDS but possibly also to ‘early phase’. Accord-
ingly, extent of ﬁbroproliferative changes on HRCTscan,
together with N-PCP-III concentration in BALF, may be
a potential clue to differentiate ‘real’ late ARDS from the
early one.
Currently, there have been few prospective clinical
studies to validate the susceptibility to ventilator-associ-
ated outcomes. The ARDS Network low tidal volume
study has suggested that excessive large tidal ventilation
induces inﬂammatory cytokines and is associated with
a known risk factor for ventilator-associated lung
injury.
31 In the present study, patients with extensive
ﬁbroproliferation shown as higher HRCT score on the
day of ARDS onset needed a longer duration of
mechanical ventilation with subsequent ventilator-asso-
ciated pneumonia and had shorter organ failure-free
days and subsequently suffered from multiple organ
failure.
Barotraumas occurring in critically ill patients inde-
pendently affects intensive care unit mortality.
38 Baro-
trauma events occur late in the course of ARDS and are
related to lung structural changes such as cystic or
ﬁbroproliferative lesions that develop over time.
39 In our
study, barotrauma occurred more than 10 days (mean 6
SD, 12.769.4 days) after the onset of ARDS and was
more frequent in patients with a higher HRCT score
(score $235) than in those with a lower HRCT score
(score <235) during the ﬁrst 28 days. Given that
a higher HRCT score at diagnosis suggests advanced
ﬁbroproliferation, our data support the relationship
between pulmonary ﬁbroproliferation and its suscepti-
bility to barotraumas.
VAP has been a causative factor of subsequent systemic
inﬂammatory syndrome resulting in multi-organ
failure.
33 The risk of VAP increases with prolonged
mechanical ventilation.
34 Furthermore, sustained and
intense inﬂammatory responses in unresolving ARDS
increase intracellular and extracellular growth of noso-
comial pathogens and increase the risk for nosocomial
infections.
40 More extensive ﬁbroproliferative changes
on HRCT scan shown as a higher CT score were associ-
ated with a longer ventilator dependency that was more
susceptible to VAP onset. These results support that
pulmonary ﬁbroproliferation of ARDS increases risk for
ventilator dependency and its associated complications.
In a previous study of 45 cases of ARDS conﬁrmed at
biopsy, patients whose conditions were shown histologi-
cally to be in the acute exudative phase had a better
prognosis than did those whose condition was shown to
be in the ﬁbroproliferative phases.
41 Persistent
Figure 5 Receiver operator characteristic (ROC) curve of
prediction of the ventilator weaning within 28 days from high-
resolution CT score. ROC curve identiﬁed the optimal cut-off
value of 210 determined by the Youden Index for prediction of
ventilator weaning at day 28 with 75% sensitivity and 76%
speciﬁcity (area under the curve, 0.77; 95% CI 0.67 to 0.88).
Figure 6 Sequential changes of Sequential Organ Failure
Assessment (SOFA) scores. The SOFA score of a patient with
a lower CT score (<210) signiﬁcantly decreased from day 1 to
day 14 (p¼0.0016). The SOFA score of a patient with a higher
CT score ($210) signiﬁcantly increased from day 1 to day 14
(p¼0.027). Four patients with a lower CT score (<210) and
nine patients with a higher CT score ($210) who died within
14 days were excluded.
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Fibroproliferative changes on HRCT in early ARDSdysregulated systemic inﬂammation leading to malad-
aptive lung repair results in pulmonary ﬁbroprolifera-
tion and progression of extrapulmonary organ
dysfunction.
5 Prolonged corticosteroid therapy attenu-
ates systemic inﬂammation and reduced duration of
mechanical ventilation.
5 In our study, the group of
patients who had less ﬁbroproliferative changes on
HRCTscans (HRCTscore, <210) showed lower mortality
and more ventilator-free days than those who had more
extensive areas of ﬁbroproliferation (HRCT score,
$210). This may suggest a relationship between the
pathologic phases of ARDS and responsiveness to treat-
ment. When more extensive and rapidly progressive
pulmonary ﬁbroproliferation resulting from intense
exaggerated systemic inﬂammation at presentation
occurs, even prolonged corticosteroid therapy may not
be effective. Whether the patients with ﬁbroproliferative
predominance have different treatment strategies
compared with those with exudative predominance has
been a vexing question.
4 Improving our understanding
of disease state and evolution of the disease may be key
to the development of the optimal therapy and their
timing. A method that could be used to evaluate and
calibrate the clinical to pathologic stages may help
prognosticate, alter supportive or therapeutic approach
to ARDS such as ventilator management and deﬁne the
treatment window for those interventions. Further
prospective studies are needed to examine the efﬁcacy of
the drugs such as corticosteroids according to the extent
of ﬁbroproliferation on HRCT scans.
There were some potential limitations. First, our study
included few patients with ARDS caused by major
trauma, multiple transfusion and others, although it
included approximately 90% of the patients who had
ARDS caused by three major etiologies (pneumonia,
aspiration, sepsis) of ARDS; thus, our study may not
sufﬁciently reﬂect all forms of ARDS. However, previous
large randomised control studies also included more
than 70% of patients with these three etiologies.
27 31
Therefore, our results may be applicable to most forms
of ARDS.
Second, many elderly patients (mean age, 75.0 years)
were included. Clinically, elderly ARDS patients show
higher morbidity and need longer duration of mechan-
ical ventilation with subsequent poorer prognosis than
the younger patients.
2 36 The age-related differences in
mortality and outcomes have been considered to be due
to the greater number of comorbid illness and higher
frequency of non-pulmonary organ system failure in
older patients.
36 In this study, pre-existing pulmonary
emphysema was seen in 32 (38%) of 85 patients.
Although no signiﬁcant differences were seen between
survivors and non-survivors in the number of a history of
cigarette smoking and a presence of emphysema, we
Table 6 Multiple logistic regression analysis of variables
potentially associated with ventilator-associated outcomes
Variable p Value OR (95% CI)
(A) Ventilator weaning within 28 days in patients with ARDS
HRCT score 0.0006 0.63* (0.48 to 0.82)
Serum albumin 0.1727 2.09 (0.72 to 6.03)
(B) The incidence of the barotrauma
HRCT score 0.0183 1.61* (1.08 to 2.38)
APACHE II 0.4724 0.92 (0.74 to 1.15)
SOFA score 0.9110 1.02 (0.68 to 1.55)
Serum albumin 0.5156 0.53 (0.08 to 3.65)
Serum LDH 0.0158 1.05 (1.01 to 1.09)
(C) The complication of the ventilator-associated
pneumonia
Liver cirrhosis 0.0286 13.34 (1.31 to 135.60)
HRCT score 0.0041 1.46* (1.13 to 1.89)
PaO2/FiO2 ratio 0.0236 0.99 (0.98 to 1.00)
*Expressed as mortality change per 10% increase in area of
attenuation with traction bronchiectasis on high-resolution CT.
APACHE II, acute physiology and chronic health evaluation II;
ARDS, acute respiratory distress syndrome; HRCT, high-resolution
CT; LDH, lactate dehydrogenase; SOFA, sequential organ failure
assessment.
Figure 7 (A) Receiver operator
characteristic (ROC) curve of
prediction of the onset of
barotrauma from high-resolution
CT score. ROC curve identiﬁed
the optimal cut-off value of 235
determined by the Youden Index
for prediction of barotraumas
onset with 73% sensitivity and
77% speciﬁcity (area under the
curve, 0.77; 95% CI 0.59 to 0.95).
(B) Comparison of the incidence of
barotraumas between patients
with the optimal cut-off value of CT
score identiﬁed from ROC curve.
The incidence of barotrauma of
a patient with a lower CT score
was signiﬁcantly lower than that of
a patient with a higher CT score.
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onset of ARDS. Such a smoking-induced chronic lung
disease could potentially affect ventilator dependency or
prognosis. Although it was problematic whether ageing
increase susceptibility to lung injury and to pulmonary
ﬁbroproliferation, further investigation of younger
patients with ARDS is needed to conﬁrm the consistency
of the results of our study.
Third, no correlation was provided with either clinical
parameters or pathologic ﬁndings in the present study.
Further investigation is necessary to compare HRCT
ﬁndings with other predictors of morbidity/mortality,
that is, inﬂammatory biomarkers such as serum IL-6 or
BAL PCP III levels. Recent studies of biopsy ﬁndings
from ARDS patients have reported the pathologic
diversity and only half proportion of typical diffuse
alveolar damage.
6 7 Regardless of the cause or pathology
of ARDS, our study highlighted the extent of lung
architectural distortion (areas with traction bronchiec-
tasis) indicating that pulmonary ﬁbroproliferation on
HRCTscans. Although ﬁbroproliferative ARDS does not
warrant different treatment strategies up to the present,
prospective evaluation of HRCT ﬁndings in patients
with ARDS would help therapeutic implications in the
development of treatment strategies based on the
extent of ﬁbroproliferation, as well as its prognostic
implications.
Fourth, when using our cut-off values of HRCT scores,
there were approximately 30% of our patients who did
not ﬁt for prediction of poor prognosis or ventilator
dependency. Recently, multiple organ failure in ARDS
patients is considered to be either as the predisposing
condition or as a consequence of ARDS.
42 If ARDS
occurs as one of the multiple organ failure, even though
pulmonary ﬁbroproliferation was mild, extrapulmonary
dysfunction could be the determinant of the outcome.
On the basis of our results, extensive HRCT abnor-
malities indicative of ﬁbroproliferative changes on the
day of ARDS diagnosis were independently predictive of
poor prognosis and prolonged mechanical ventilation
and were also associated with subsequent multiple organ
failure. Pulmonary ﬁbroproliferation that occurs early in
ARDS patients increases mortality risk by increasing
susceptibility to ventilator dependency and its associated
complications.
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